Has Whoopi Goldberg confirmed she uses Mounjaro?

Yes. Goldberg disclosed her use of Mounjaro (tirzepatide) for weight management during a segment on *The View*. She has not publicly detailed her dosing, duration of use, or whether she has paused or adjusted treatment.

What happens when you stop taking Mounjaro?

Clinical trial data from SURMOUNT-4, published in *JAMA*, shows that patients who discontinued tirzepatide after 36 weeks of treatment regained approximately two-thirds of lost weight over the following year. This pattern is consistent across GLP-1 receptor agonists and reflects the re-emergence of the physiological appetite and metabolic signals that the drug suppresses.

Can you take a lower dose of Mounjaro for maintenance?

Some clinicians are using dose-reduction strategies, tapering patients from higher induction doses to the lowest dose that maintains weight. Tirzepatide is available from 2.5 mg to 15 mg. Formal randomized trials of this approach are ongoing, but early clinical reports suggest it is viable for some patients.

Is Mounjaro safe for women over 65?

Tirzepatide has been studied in adults across age ranges, including older adults. The primary age-specific concerns are lean mass loss (sarcopenia), bone density reduction, and gastrointestinal side effects, which can be more impactful in older patients. The FDA prescribing information does not contraindicate use based on age alone, but the HealthRX.com Medical Team strongly recommends concurrent resistance training, protein optimization, and DEXA monitoring for any patient over 60.

Does Medicare cover Mounjaro for weight loss?

As of 2026, Medicare Part D coverage for anti-obesity medications remains limited. Mounjaro is more consistently covered when prescribed for its FDA-approved type 2 diabetes indication. Legislative proposals to expand Medicare coverage for obesity pharmacotherapy are under consideration but have not been enacted. Patients should verify coverage with their specific plan.

Whoopi Goldberg, Maintenance, and What Happens If You Stop

By HealthRX.com Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Clinical image for Whoopi Goldberg, Maintenance, and What Happens If You Stop Image: HealthRX.com clinical image

What Whoopi Goldberg Has Said Publicly

Goldberg disclosed her use of Mounjaro on The View, ABC's long-running daytime talk show. She spoke about using the medication for weight management, joining a growing list of public figures who have been open about GLP-1 receptor agonist therapy. Her disclosure is significant in part because of her audience: The View draws millions of viewers, many of them women over 50, a demographic that faces distinct metabolic challenges and for whom GLP-1 prescribing is rising rapidly.

Whether Goldberg is currently on Mounjaro, has adjusted her dose, or has at any point paused the medication has not been publicly detailed beyond her initial disclosure. The HealthRX.com Medical Team is not speculating on her current regimen. What we can do is use her public story as a clinical entry point into the two questions her audience is most likely asking: What happens if I stop? and What does staying on this look like?

Mounjaro: A Quick Mechanism Refresher

Tirzepatide (brand name Mounjaro) is a dual GIP/GLP-1 receptor agonist approved by the FDA for type 2 diabetes and, under the brand name Zepbound, for chronic weight management. It works through two incretin pathways simultaneously. GLP-1 receptor activation slows gastric emptying, suppresses glucagon secretion, and acts on hypothalamic appetite centers to reduce hunger. GIP receptor activation appears to enhance insulin sensitivity and may contribute to fat oxidation, though the full mechanism is still being studied.

In the SURMOUNT-1 trial, participants without diabetes lost a mean of 20.9% of body weight on the highest dose (15 mg) over 72 weeks. That is a degree of weight reduction previously seen only with bariatric surgery. The SURMOUNT-1 results published in The New England Journal of Medicine changed expectations for what pharmacotherapy could accomplish.

The Discontinuation Problem: What the Data Shows

The more relevant trial for this article is SURMOUNT-4. Published in JAMA in 2024, it addressed the question directly: what happens after you stop tirzepatide?

Participants who had lost weight on tirzepatide for 36 weeks were randomized to either continue treatment or switch to placebo. Over the following 52 weeks, the placebo group regained approximately two-thirds of the weight they had lost. The continuation group kept losing. The gap between the two arms at 88 weeks was roughly 18 percentage points of body weight.

This is not unique to tirzepatide. The STEP 1 trial extension for semaglutide (Wegovy) showed a similar rebound pattern, with participants regaining about two-thirds of lost weight within a year of stopping. The biology is consistent: GLP-1 medications suppress appetite through central and peripheral mechanisms that reverse when the drug clears the system.

The HealthRX.com Medical Team puts it bluntly: GLP-1 receptor agonists treat obesity the way antihypertensives treat high blood pressure. Stopping the medication does not cure the underlying condition. For most patients, the physiological drivers of weight regain (reduced energy expenditure, increased hunger hormones, metabolic adaptation) reassert themselves within weeks of discontinuation.

Why This Matters More for Older Women

Goldberg was 68 when she made her disclosure. Age is not a footnote here. It changes the clinical calculus in several ways.

Sarcopenia risk. Weight loss in older adults involves disproportionate loss of lean muscle mass. A 2023 study in The Lancet found that roughly 25-40% of weight lost on GLP-1 therapy can be lean mass. For a woman in her late 60s, losing muscle is a serious concern: it increases fall risk, accelerates functional decline, and worsens metabolic health independent of fat mass. Weight regain after discontinuation tends to favor fat over muscle, which means a stop-start cycle could leave someone with less muscle and more fat than when they began.

Bone density. Rapid weight loss in postmenopausal women is associated with accelerated bone mineral density loss. The Endocrine Society's clinical guidelines flag this as a concern in any older adult weight management program. Discontinuation and regain cycling could compound this risk.

Cardiovascular context. The SELECT trial demonstrated that semaglutide reduced major adverse cardiovascular events by 20% in adults with established cardiovascular disease and obesity, as published in NEJM. If a patient in Goldberg's age range is deriving cardiovascular benefit from GLP-1 therapy, stopping introduces a risk beyond weight regain alone.

What "Maintenance" Actually Looks Like

The clinical reality is that most patients who respond well to tirzepatide will need ongoing treatment. But "ongoing" does not necessarily mean "maximum dose forever." Maintenance strategies are evolving.

Dose reduction. Some clinicians taper patients to the lowest effective dose once weight loss plateaus. Tirzepatide is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg formulations. A patient who achieved target weight on 15 mg may maintain results at 5 mg or 7.5 mg, reducing both side effect burden and cost. Formal trials of dose-reduction maintenance strategies are underway, but early clinical experience supports this approach for a subset of patients.

Combination with structured exercise. Resistance training during and after GLP-1 therapy is the single strongest intervention for preserving lean mass. A 2024 analysis in JAMA Network Open showed that patients who combined GLP-1 therapy with twice-weekly resistance training lost a similar amount of total weight but retained significantly more muscle compared to medication alone. For older women, the HealthRX.com Medical Team considers this non-negotiable, not optional.

Protein intake. Current evidence reviewed in The American Journal of Clinical Nutrition supports 1.2-1.6 g of protein per kilogram of body weight daily for older adults on calorie-restricted or appetite-suppressing regimens. GLP-1 medications reduce appetite broadly, which can lead to inadequate protein intake if patients are not deliberately tracking macronutrients.

Monitoring. The HealthRX.com Medical Team recommends that any patient over 60 on GLP-1 therapy get baseline and annual DEXA scans, regular assessment of grip strength and gait speed, and quarterly metabolic panels. This is especially true for women, given the intersection of menopause, osteoporosis risk, and the metabolic changes that come with aging.

At a glance

Confirmed use: Whoopi Goldberg publicly disclosed Mounjaro (tirzepatide) use on The View for weight management.
Discontinuation data: SURMOUNT-4 showed ~two-thirds of lost weight regained within a year of stopping tirzepatide.
Not a cure: GLP-1 medications manage obesity; they do not resolve the underlying metabolic drivers.
Age-specific risks: Older women face compounded risks from lean mass loss, bone density reduction, and cardiovascular changes if therapy is stopped abruptly.
Maintenance is the plan: Dose reduction, resistance training, adequate protein, and regular monitoring form the clinical framework for long-term use.

The Cost and Access Question

Maintenance therapy means ongoing cost. Mounjaro's list price exceeds $1,000 per month without insurance. For Goldberg, this is presumably not a barrier. For the millions of women watching her discuss the medication on daytime television, it is the central obstacle. Insurance coverage for GLP-1 medications in the context of weight management (as opposed to diabetes) remains inconsistent. Medicare Part D, which covers most Americans over 65, has historically excluded anti-obesity medications, though legislative efforts to change this are ongoing as of 2026.

The HealthRX.com Medical Team notes that the discontinuation problem and the access problem are the same problem. If a patient cannot afford continuous treatment, the clinical expectation should be weight regain. Planning for that reality (through exercise programming, dietary strategy, and metabolic monitoring) is not defeatism. It is responsible medicine.

The HealthRX.com Medical Team Take

Goldberg's willingness to discuss Mounjaro on national television did something clinical trials cannot: it gave millions of older women permission to ask their doctors about GLP-1 therapy. That is genuinely valuable.

The clinical picture, though, requires honesty. Tirzepatide is the most effective anti-obesity medication ever approved. It is also a medication that, based on every discontinuation trial conducted to date, most patients will need to take indefinitely to maintain results. For a 68-year-old woman, the calculation involves not just weight but muscle mass, bone health, cardiovascular risk, and functional independence.

Stopping is not failure. But stopping without a plan (without resistance training, without protein targets, without monitoring) is where the real clinical risk lives. The data from SURMOUNT-4 is clear: the medication works as long as you take it. The open question for every patient, famous or not, is what the long-term treatment architecture looks like. That conversation, between patient and physician, informed by the data rather than by celebrity culture, is where the best outcomes will come from.

Frequently asked questions

›